Abstract 2271
Background
No previous study has evaluated the prognostic value of coagulation factors in patients with early-stage natural killer/T-cell lymphoma (NKTCL). The aim of this study was to investigate the relationships between coagulation function and clinical response and prognosis in patients with early-stage NKTCL.
Methods
The data of patients with stage I/II NKTCL who were treated in Cancer Hospital, Chinese Academy of Medical Sciences from January 2008 to January 2019 were collected and studied retrospectively. Data included patients’ clinical characteristics and related indexes of coagulation function before treatment (preoperative activated partial thromboplastin time (APTT), prothrombin time (PT), prothrombin time activity (PTA), fibrinogen (FIB), international normalized ratio (INR), D-dimer, and platelet count (PLT)). The cut-off value was set as the median of pretreatment coagulation factors.
Results
A total of 159 patients with stage I/II NKTCL were included in this study. Abnormal coagulation function was found in nearly half of (49.69%) patients, and increased D-dimer(16.28%) and FIB(11.25%) were the most common abnormalities. Univariate analysis showed that increased D-dimer level (P < 0.001) and increased FIB level (P = 0.021) reduced complete remission (CR) rate. In addition to other prognostic factors including Eastern cooperative oncology group (ECOG) score≥2, B symptom, increased lactate dehydrogenase (LDH) level, increased D-dimer level was also demonstrated to be associated with the unfavorable progression-free survival (PFS) (P = 0.003) and overall survival (OS) (P = 0.002). Multivariate analysis indicated that increased D-dimer level was an independent factor for poor clinical response (P = 0.008), PFS (P = 0.021) and OS (P = 0.007).
Conclusions
Our study suggested that elevated pretreatment coagulation factors especially D-dimer and plasma FIB were unfavorable predictors for clinical response, OS and PFS in early-stage NKTCL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dong Mei.
Funding
The Cancer Foundation of China, Beijing Hope Marathon Project Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2504 - Inadequacy of current definition and staging system of Medication-Related Osteonecrosis of Jaw (MRONJ) released by AAOMS : a Computed Tomography study in 151 cancer and myeloma patients
Presenter: Vittorio Fusco
Session: Poster Display session 1
Resources:
Abstract
2459 - Does bevacizumab increase joint pain ? Preliminary results of BEVARTHRALGIA Study
Presenter: Vauleon Enora
Session: Poster Display session 1
Resources:
Abstract
4913 - Prostatic cancer androgen deprivation therapy and bone health in carcinoma prostate.
Presenter: Gouri Shankar Bhattacharyya
Session: Poster Display session 1
Resources:
Abstract
1352 - Patterns of care for patients with metastatic bone disease in solid tumors – a cross-sectional study (SAKK 95/16)
Presenter: Michael Mark
Session: Poster Display session 1
Resources:
Abstract
6002 - Infection-Related Mortality in Different Types of Cancers
Presenter: Mohamed Gouda
Session: Poster Display session 1
Resources:
Abstract
5643 - Survival Trends in Critically ill Oncology Patients: impact of patient’s eligibility to post-ICU chemotherapy
Presenter: Edith Borcoman
Session: Poster Display session 1
Resources:
Abstract
3097 - Development and validation of a multivariable prediction model for 6-month mortality in older cancer patients: the GeriAtrIc-Tumor Score of PrEdiction for Early Death (GAIT SPEED)
Presenter: Angeli Angeli
Session: Poster Display session 1
Resources:
Abstract
856 - A Longitudinal Tracking and Quantitative Assessment of Paclitaxel-Induced Peripheral Neurotoxicity
Presenter: Ayumu Matsuoka
Session: Poster Display session 1
Resources:
Abstract
1662 - Efficiency of controlled cryotherapy in prevention of chemotherapy induced peripheral neuropathy (CIPN)
Presenter: Trudi Schaper
Session: Poster Display session 1
Resources:
Abstract
2766 - The Validity of Evaluations for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Presenter: Teppei Yamada
Session: Poster Display session 1
Resources:
Abstract